EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models

Antonio Carlos Tallon-Cobos, Konstantinos Vazaios, Piotr Waranecki, Marliek van Hoesel, Annelisa Cornel, Benjamin Schwalm, Norman Mack, Ella de Boed, Jasper van der Lugt, Stefan Nierkens, Marcel Kool, Eelco W Hoving und 2 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci193332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Antonio Carlos Tallon-Cobos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for pediatric oncology, Utrecht, Netherlands. Hauptthemen laut MEDLINE: Ependymoma, Gangliosides, Brain Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HE/MSCA, KiTZ Maxima Collaborative Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpendymomaGangliosidesBrain NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysDisease Models, Animal

Stichwörter der Autor:innen

Brain cancerCancer immunotherapyImmunologyNeuroscienceOncology

Substanzen

Gangliosidesganglioside, GD2Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Princess Máxima Center for pediatric oncology, Utrecht, Netherlands.
  • Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Consortium (DKTK), Heidelberg, Germany.
  • University Medical Center Utrecht, Utrecht, Netherlands.
  • Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Förderung

  • HE/MSCA
  • KiTZ Maxima Collaborative Grant

Zitieren

APA

Tallon-Cobos, A. C., Vazaios, K., Waranecki, P., van Hoesel, M., Cornel, A., Schwalm, B., Mack, N., de Boed, E., van der Lugt, J., Nierkens, S., Kool, M., Hoving, E. W., Metselaar, D. S., & Hulleman, E. (2026). CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models. Journal of Clinical Investigation. https://doi.org/10.1172/jci193332

Vancouver

Tallon-Cobos AC, Vazaios K, Waranecki P, van Hoesel M, Cornel A, Schwalm B, et al. CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models. Journal of Clinical Investigation. 2026. doi:10.1172/jci193332

BibTeX
@article{TallonCobos2026,
  author = {Tallon-Cobos, Antonio Carlos and Vazaios, Konstantinos and Waranecki, Piotr and van Hoesel, Marliek and Cornel, Annelisa and Schwalm, Benjamin and Mack, Norman and de Boed, Ella and van der Lugt, Jasper and Nierkens, Stefan and Kool, Marcel and Hoving, Eelco W and Metselaar, Dennis S and Hulleman, Esther},
  title = {CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci193332}
}
Kostenlos starten →